Ferroptosis in Neurodegeneration

Ferroptosis in Neurodegeneration

Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation, first formally defined by Brent Stockwell and colleagues in 2012. Unlike apoptosis, necrosis, or necroptosis, ferroptosis is characterized by the accumulation of lethal levels of lipid hydroperoxides in cellular membranes, catalyzed by free iron and labile iron pools. The brain is particularly vulnerable to ferroptosis due to its high polyunsaturated fatty acid (PUFA) content, elevated oxygen consumption, regionally concentrated iron stores, and relatively limited antioxidant capacity. Ferroptosis has been implicated as a significant contributor to neuronal loss in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons), [ALS](/diseases/amyotrophic-lateral-sclerosis), Friedreich's ataxia, and [neurodegeneration with brain iron accumulation](/diseases/nbia) disorders.

Molecular Mechanisms of Ferroptosis

Iron Metabolism and the Labile Iron Pool

Iron homeostasis is critical for neuronal survival. Under physiological conditions, iron is safely sequestered in ferritin or incorporated into iron-sulfur clusters and heme groups. ferroptosis is triggered when the labile iron pool (LIP)—a transient, redox-active pool of loosely chelated Fe²⁺—expands beyond the cell's buffering capacity [@gpx].

Key regulators of neuronal iron homeostasis include:

Ferroptosis in Neurodegeneration

Ferroptosis is a form of regulated cell death driven by iron-dependent lipid peroxidation, first formally defined by Brent Stockwell and colleagues in 2012. Unlike apoptosis, necrosis, or necroptosis, ferroptosis is characterized by the accumulation of lethal levels of lipid hydroperoxides in cellular membranes, catalyzed by free iron and labile iron pools. The brain is particularly vulnerable to ferroptosis due to its high polyunsaturated fatty acid (PUFA) content, elevated oxygen consumption, regionally concentrated iron stores, and relatively limited antioxidant capacity. Ferroptosis has been implicated as a significant contributor to neuronal loss in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons), [ALS](/diseases/amyotrophic-lateral-sclerosis), Friedreich's ataxia, and [neurodegeneration with brain iron accumulation](/diseases/nbia) disorders.

Molecular Mechanisms of Ferroptosis

Iron Metabolism and the Labile Iron Pool

Iron homeostasis is critical for neuronal survival. Under physiological conditions, iron is safely sequestered in ferritin or incorporated into iron-sulfur clusters and heme groups. ferroptosis is triggered when the labile iron pool (LIP)—a transient, redox-active pool of loosely chelated Fe²⁺—expands beyond the cell's buffering capacity [@gpx].

Key regulators of neuronal iron homeostasis include:

• Transferrin receptor 1 (TfR1): Imports transferrin-bound iron into neurons. Upregulated in ferroptosis-susceptible cells.
• Ferritin (FTH1/FTL): Sequesters excess iron. Ferritinophagy—selective autophagic degradation of ferritin via NCOA4—releases stored iron and promotes ferroptosis ([Mancias et al., 2014](https://doi.org/10.1038/nature13148)).
• Ferroportin (SLC40A1): The sole cellular iron exporter. Reduced ferroportin expression increases iron retention and ferroptosis susceptibility.
• Hepcidin: The master regulator of systemic iron homeostasis that degrades ferroportin. Elevated in neuroinflammatory conditions.

Lipid Peroxidation: The Executioner

The lethal event in ferroptosis is the peroxidation of polyunsaturated fatty acid phospholipids (PUFA-PLs) in cellular membranes, particularly phosphatidylethanolamines (PE) containing arachidonic acid (AA) or adrenic acid (AdA):

Products of lipid peroxidation include malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), both of which are elevated in alzheimers brains and serve as biomarkers of ferroptotic damage [@irona].

The System Xc⁻–GSH–GPX4 Axis

The primary defense against ferroptosis is the system Xc⁻–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis:

• System Xc⁻: A cystine/glutamate antiporter (SLC7A11/SLC3A2) that imports cystine in exchange for glutamate. Cystine is reduced intracellularly to cysteine, the rate-limiting substrate for GSH synthesis. Importantly, excitotoxic levels of extracellular glutamate inhibit system Xc⁻, linking excitotoxicity directly to ferroptosis ([Dixon et al., 2012](https://doi.org/10.1016/j.cell.2012.03.042)).
• Glutathione (GSH): The most abundant intracellular antioxidant, serving as a cofactor for GPX4. GSH depletion is a hallmark of ferroptosis.
• GPX4: The only enzyme that reduces lipid hydroperoxides within biological membranes to non-toxic lipid alcohols. GPX4 is the central gatekeeper against ferroptosis. Its inactivation (by RSL3 or genetic deletion) is sufficient to trigger ferroptosis ([Yang et al., 2014](https://doi.org/10.1016/j.cell.2013.12.010)).

Alternative Anti-Ferroptotic Pathways

Beyond GPX4, several parallel defense systems have been identified:

• FSP1-CoQ₁₀ pathway: ferroptosis suppressor protein 1 (FSP1/AIFM2) reduces ubiquinone (CoQ₁₀) to ubiquinol, which traps lipid peroxyl radicals. This pathway operates independently of GPX4 ([Doll et al., 2019](https://doi.org/10.1038/s41586-019-1705-2)).
• DHODH pathway: Dihydroorotate dehydrogenase reduces CoQ₁₀ in the mitochondrial inner membrane, providing compartment-specific ferroptosis defense.
• GCH1-BH4 pathway: GTP cyclohydrolase 1 synthesizes tetrahydrobiopterin (BH4), which acts as a radical-trapping antioxidant that selectively protects PUFAs from oxidation.

Ferroptosis in Specific Neurodegenerative Diseases

Alzheimer's Disease

The connection between ferroptosis and Alzheimer's disease is supported by extensive evidence:

• Iron accumulation: AD brains show significantly elevated iron levels in the hippocampus, cortical lobes, and basal ganglia compared to age-matched controls. Iron deposition correlates with amyloid-β plaque burden and neurofibrillary tangle formation ([Ayton et al., 2020](https://doi.org/10.1001/jamaneurol.2019.4849)).
• amyloid-beta-iron interaction: amyloid-beta binds iron with high affinity and promotes reduction of Fe³⁺ to redox-active Fe²⁺, catalyzing oxidative damage. Iron in turn promotes amyloid-beta aggregation, creating a pathogenic positive feedback loop ([Bao et al., 2024](https://doi.org/10.1038/s41419-024-07152-0)).
• Tau protein and iron: Iron accumulation accelerates tau hyperphosphorylation and aggregation, while tau itself regulates neuronal iron export through APP-mediated ferroportin trafficking. Pathological tau disrupts this process, trapping iron intracellularly.
• GPX4 downregulation: AD brains show reduced GPX4 expression and elevated lipid peroxidation markers (MDA, 4-HNE), indicating compromised anti-ferroptotic defense ([Bao et al., 2024](https://doi.org/10.1038/s41419-024-07152-0)).
• Lipid raft vulnerability: Iron-associated lipid peroxidation in AD is particularly concentrated in lipid rafts, cholesterol-enriched membrane microdomains critical for synaptic signaling, with decreased ferroptosis suppressors in these compartments ([Thorwald et al., 2025](https://doi.org/10.1002/alz.14541)).

Parkinson's Disease

Parkinson's disease shows compelling links to ferroptosis:

• Substantia nigra iron: The substantia nigra pars compacta—the primary site of neurodegeneration in PD—has the highest iron concentration of any brain region, making dopaminergic neurons intrinsically vulnerable to ferroptosis.
• Dopamine-iron interaction: Dopamine oxidation generates reactive quinones and hydrogen peroxide, which combine with iron to amplify oxidative-stress through Fenton chemistry.
• α-Synuclein and iron: α-Synuclein binds iron, and iron promotes α-synuclein aggregation. Conversely, α-synuclein oligomers increase neuronal iron uptake by modulating transferrin receptor expression.
• DJ-1 and ferroptosis: Loss-of-function mutations in DJ-1 (PARK7), a cause of familial PD, increase ferroptosis sensitivity by impairing GSH synthesis and antioxidant defense.

Ferroptosis in Frontotemporal Dementia

FTD shows significant ferroptosis vulnerability, particularly in forms associated with TDP-43 and tau pathology:

• TDP-43 and iron dysregulation: TDP-43 pathology in FTD impairs mitochondrial function, increasing oxidative stress and iron accumulation. FTD patients show elevated CSF ferritin, a marker of brain iron overload.
• C9orf72 and ferroptosis: FTD-ALS patients with C9orf72 expansions show increased ferroptosis sensitivity due to GSH depletion and impaired GPX4 function.
• TAU and iron interactions: FTD with tau pathology (Pick's disease, CBD, PSP) shows similar iron-tau interactions as seen in AD, with iron promoting tau aggregation and tau disruption of iron export.
• Lipid peroxidation: FTD brain tissue shows elevated lipid peroxidation markers (4-HNE, MDA) correlating with disease severity.
• Therapeutic potential: GPX4 activators, iron chelators, and lipid peroxidation inhibitors represent promising therapeutic strategies for FTD.

Ferroptosis in Huntington's Disease

In Huntington's disease, ferroptosis contributes to striatal neurodegeneration:

• Mutant huntingtin impairs iron homeostasis, leading to iron accumulation in the striatum and cortex.
• ACSL4 expression is upregulated in HD models, increasing the pool of peroxidation-susceptible membrane PUFAs.
• Ferroptosis inhibitors (ferrostatin-1, liproxstatin-1) rescue neuronal death in HD cellular and animal models.

Friedreich's Ataxia

[Friedreich's ataxia](/diseases/friedreichs-ataxia) is perhaps the most direct link between iron dyshomeostasis and neurodegeneration:

• Loss of frataxin (a mitochondrial iron-sulfur cluster assembly protein) leads to mitochondrial iron accumulation, impaired electron transport chain function, and massive oxidative stress.
• ferroptosis is a primary mechanism of cardiomyocyte and neuronal death in Friedreich's Ataxia.

NBIA Disorders

[NBIA disorders](/diseases/nbia), including PKAN, represent genetic conditions where dysregulated iron metabolism directly causes neurodegeneration:

• PKAN is caused by mutations in pantothenate kinase 2 (PANK2), which impairs CoA synthesis and leads to iron accumulation in the globus pallidus.
• PLA2G6-associated neurodegeneration (PLAN) involves deficiency of a phospholipase that maintains membrane phospholipid integrity, linking lipid metabolism directly to iron-dependent neurodegeneration.

Interaction with Other Pathological Mechanisms

ferroptosis intersects with multiple other neurodegenerative mechanisms:

• excitotoxicity: Excessive extracellular glutamate competitively inhibits system Xc⁻, depleting intracellular cysteine and GSH, directly promoting ferroptosis. This is a major convergence point between excitotoxic and ferroptotic pathways.
• neuroinflammation: Pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) upregulate pro-ferroptotic enzymes (ALOX15, ALOX12) while suppressing GPX4 expression through STAT3-dependent transcriptional repression. Conversely, ferroptotic cells release DAMPs that amplify microglial releases iron and promotes ferroptosis. Impaired lysosomal function, common in neurodegeneration, disrupts iron recycling pathways.
• Biometal dyshomeostasis: ferroptosis is part of the broader disruption of metal homeostasis in neurodegeneration, where iron, copper, and zinc all contribute to oxidative damage through distinct mechanisms.

Therapeutic Strategies Targeting Ferroptosis

Iron Chelation

• Deferiprone: A brain-penetrant iron chelator that has shown promise in clinical trials for PD (FAIR-PARK II trial) and Friedreich's Ataxia by reducing brain iron levels.
• Deferoxamine: Reduces amyloid-beta-associated iron toxicity in preclinical AD models but has limited blood-brain-barrier penetration.

Lipid Peroxidation Inhibitors

• Ferrostatin-1 and Liproxstatin-1: Potent radical-trapping antioxidants that specifically inhibit lipid peroxidation. Highly effective in preclinical models but have pharmacokinetic limitations.
• Vitamin E (α-tocopherol): A natural lipophilic radical-trapping antioxidant that suppresses ferroptosis. Clinical trials in AD have shown modest effects.

GPX4 Enhancers

• Selenium supplementation: Selenium is incorporated into GPX4 as selenocysteine. Selenium supplementation boosts GPX4 activity and protects against ferroptosis in preclinical models.
• KCF18 and ebselen: GPX4 stabilizers and expression enhancers that have shown neuroprotective effects in experimental settings ([Bao et al., 2024](https://doi.org/10.1038/s41419-024-07152-0)).

System Xc⁻ and GSH Restoration

• N-acetylcysteine (NAC): Provides cysteine for GSH synthesis, bypassing system Xc⁻ inhibition.
• Exercise: Aerobic exercise activates the system Xc⁻/GPX4 signaling axis in the prefrontal cortex, upregulates ferritin light chain, downregulates lipid peroxidation markers, and ameliorates cognitive deficits in AD mouse models ([Li et al., 2025](https://doi.org/10.3389/fcell.2025.1622544)).

Ferroptosis Cross-Disease Comparison

Disease Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Iron accumulation | Cortical/hippocampal | Substantia nigra | Motor neurons | Frontal cortex/striatum | Striatum/cortex |
| GPX4 status | Decreased | Reduced | Compromised | Impaired | Reduced |
| Lipid peroxidation markers | MDA, 4-HNE elevated | 4-HNE increased | Severe peroxidation | 4-HNE, MDA elevated | Elevated |
| Key mechanism | Aβ-Fe²⁺ loop | Neuromelanin-Fe²⁺ | Oxidative stress | TDP-43/mitochondrial | mHtt-Fe²⁺ |
| Therapeutic target | Iron chelation + GPX4 | Iron chelation | Ferroptosis inhibitors | GPX4 activators | ACSL4 inhibition |

Shared Ferroptotic Vulnerabilities

All neurodegenerative diseases share these core ferroptotic vulnerabilities:

Disease-Specific Mechanisms

• AD: Aβ binds Fe³⁺, promotes Fe²⁺ reduction → Fenton chemistry → lipid peroxidation
• PD: Neuromelanin depletes → iron sequestration lost → SNc vulnerability
• ALS: SOD1/G93A mutations → ROS accumulation → GPX4 inactivation
• FTD: TDP-43 pathology → mitochondrial dysfunction → iron dysregulation
• HD: mHtt disrupts iron homeostasis → striatal iron accumulation → ACSL4 upregulation

Pathway & Interaction Diagram

Interactive diagram showing Ferroptosis's key relationships in the SciDEX knowledge graph (15 connections shown).

See Also

• [Huntington's Disease](/diseases/huntingtons)
• [All Mechanisms](/mechanisms)
• [Oxidative Stress](/mechanisms/oxidative-stress)
• [Iron Metabolism](/mechanisms/iron-homeostasis-neurodegeneration)
• [Cell Death Pathways](/mechanisms/cell-death-pathways-neurodegeneration)
• [Lipid Metabolism Dysfunction Comparison](/mechanisms/lipid-metabolism-dysfunction-comparison)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Extracellular Matrix Stiffness Modulation](/hypothesis/h-725c62e9) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: PIEZO1

Pathway Diagram

The following diagram shows the key molecular relationships involving Ferroptosis in Neurodegeneration discovered through SciDEX knowledge graph analysis: